Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05653232 · ClinicalTrials.gov registry record · NA
Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients
A NA study of HCV, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 9
- Study locations
NCT05653232: Recruiting NA study of HCV, sponsored by Johns Hopkins University.
NCT05653232 is a NA study of HCV that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 120 participants, below the 184-participant average among 8 other HCV trials with a reported enrollment target (35% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05653232, a NA study of HCV, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study is being done to find out the best time to start medication for Hepatitis C Virus (HCV) in HCV-negative recipients of HCV-positive (HCV D+/R-) kidney transplants. Participants will be randomized into one of two groups: Arm 1 - Prophylaxis: This group will start the HCV medication before transplant and will take a shorter course of HCV medication for 2 weeks. Arm 2 - Transmit and Treat: This group will start the HCV medication after transplant and will take the full course (12 weeks) of HCV medication.
Primary Outcome
Proportion of events in each arm.
Conditions Studied
Interventions
- OTHER Prophylaxis (P2W)
- OTHER Transmit and Treat (T&T)
Study Locations (9)
California
- University of California San Diego - La Jolla
- Loma Linda University Health - Loma Linda
New York
- NYU Langone Health - New York
- Icahn School of Medicine at Mount Sinai - New York
Maryland
- Johns Hopkins University - Baltimore
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Utah
- University of Utah Medical Center - Salt Lake City
Virginia
- Virginia Commonwealth University - Richmond
Wisconsin
- University of Wisconsin, Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-04-19 |
| Est. Completion | 2027-03 |
| Phase | NA |
What NCT05653232 shows while recruiting
NCT05653232 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 184-participant average among 8 other HCV trials with a reported enrollment target (35% lower).
The record links to 1 condition, with HCV appearing as the primary indexed condition, and to 2 interventions - of which Prophylaxis (P2W) is the first listed.
NCT05653232 lists 9 locations in 7 states (California, New York, Maryland).
Frequently Asked Questions
What is clinical trial NCT05653232 about?
NCT05653232 is a clinical study titled "Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients". This study is being done to find out the best time to start medication for Hepatitis C Virus (HCV) in HCV-negative recipients of HCV-positive (HCV D+/R-) kidney transplants. Participants will be randomized into one of two groups: Arm 1 - Prophylaxis: This group will start the HCV medication before ...
What is the current status of trial NCT05653232?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-04-19. Estimated completion is 2027-03.
What conditions does trial NCT05653232 study?
This clinical trial studies the following conditions: HCV.
What interventions are being tested in trial NCT05653232?
The interventions under investigation include: Prophylaxis (P2W) (OTHER), Transmit and Treat (T&T) (OTHER).
Who is sponsoring clinical trial NCT05653232?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05653232 being conducted?
This trial has 9 study locations across California, Maryland, New York, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05653232's enrollment target sits among peer trials
120 6th of 8 higher than 3 of 8 other HCV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HCV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Setting Focus Overdose Prevention Intervention
RECRUITING · NA
-
Appalachian Partnership to Reduce Disparities (Aim 2)
RECRUITING · NA
-
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
ACTIVE NOT RECRUITING · NA
-
Integrated HIV Prevention and HCV Care for PWID
ACTIVE NOT RECRUITING · NA
-
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
ACTIVE NOT RECRUITING
-
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI